Avacta Group’s Alastair Smith discusses interim results, major milestones in the next 3-6 months, COVID testing developments and appointing Stifel as joint broker in this exclusive interview with DirectorsTalk.
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that the BAMS assay to detect the SARS-CoV-2 virus
Listed biotechnology business Avacta Group has hailed a “period of significant advancement” in its interim results, with “several momentous milestones” now on the horizon. The company, which as sites in
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced the appointment of Stifel Nicolaus Europe Limited as joint broker
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced its unaudited interim results for the six-month period ended
York-based life sciences business Integumen has announced progress on its COVID-19 wastewater detection system, Microtox PD, in collaboration with Modern Water plc, Avacta Group and Aptamer Group Limited. Integumen is
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has noted the update by Integumen plc (LON:SKIN) provided today regarding their ongoing development of Affimer-based sensors for the coronavirus in
DirectorsTalk would like to highlight that the article from TheBusinessdesk.com has now been deleted and DirectorsTalk would also like to mention that Avacta is not involved in the antibody test
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, will announce its unaudited interim results for the 6 months ended 30 June 2020 on Monday, 28 September 2020.
Alastair Smith gives more detail on their latest announcement that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
